| C35 | Maintaining high-yield HIV testing activities in Zambia during the COVID-19 pandemic | E-poster | HIV prevention adaptations during COVID-19 |
| C33 | Mailout HIV self-testing: overview of the GetaKit initiative in Ottawa, Canada | E-poster | HIV self-testing |
| A2 | Low-level HIV-1 viral load predicts virologic failure in antiretroviral experienced individuals in Botswana | E-poster | Viral fitness, persistence and resistance |
| B46 | Lower HIV reservoir size in individuals who maintain higher CD4+ T cells counts prior to antiretroviral therapy initiation: the Strategic Timing of Antiretroviral Treatment (START) HIV reservoir study | E-poster | Cure interventions |
| B60 | Low viral suppression in children < 3 years old on two protease inhibitor formulations in Kenya, 2015-2019 | E-poster | Drug formulations for infants and children |
| B35 | Low risk of losing the undetectable viral load status in people with HIV switching to dual therapy | E-poster | Regimen simplification and switch studies |
| C5 | Low recency in HIV testing among injection opioid users seeking treatment: associated characteristics and implications for HIV prevention | E-poster | Epidemiology of HIV in people who use drugs |
| B15 | Low rates of testing for sexually transmitted infections in an insured cohort of men and women living with HIV | E-poster | Syphilis and other sexually transmitted infections |
| B24 | Low proportion of individuals develop Metabolic Syndrome (MetS) or hepatic fibrosis after switch to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in virologically suppressed patients: a post-hoc metabolic analysis | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| C27 | Low PrEP uptake among gay, bisexual, and other men who have sex with men in five Asian countries: results of the Asia Pacific MSM Internet Survey | E-poster | PrEP |